Shares of Relay Therapeutics surged 12.1% to $22.50 on August 13, extending a rally fueled by a cascade of Wall Street upgrades anchored by growing confidence in the company's lead cancer drug. The move tests whether investors are paying a fair price for a company that has no approved products and burned through $213 million in cash over the past year.

  • A $5 Price-Target Hike Signals Real Conviction, Not Just Routine Optimism. Citizens JMP raised its price target to $26 from $21 while maintaining a Market Outperform rating.

The firm cited progress in breast cancer treatment development, viewing Relay as an emerging player with potential for a backbone drug in breast cancer. Citizens isn't alone: Barclays just raised its target to $30 from $27 , and Canaccord set a $29 target emphasizing the drug's potential in precision oncology.

The average analyst target sits at $24.82, with a consensus "Strong Buy" rating. At $22.50, the stock is already trading above that average — a sign the market may be pricing in best-case outcomes.

  • The Drug Works Across Multiple Cancers, and That Widens the Revenue Runway. The drug at the center of this story targets a specific genetic mutation (PIK3CA) driving certain breast cancers and vascular disorders. In heavily pre-treated breast cancer patients, it delivered a median progression-free survival of 11.1 months — a strong showing. In a separate triplet combination study, 44% of patients saw their tumors shrink measurably, with 85% showing some tumor reduction.

In vascular anomalies, 60% of patients achieved a significant volumetric response, surpassing expectations. Each indication that succeeds adds a potential revenue stream.

  • The Cash Runway Is Comfortable, but the Burn Rate Demands Results. Relay ended the most recent quarter with $656.8 million in cash, providing runway into 2029. But over the last 12 months the company posted just $10.7 million in revenue against $272.7 million in losses.

Outstanding shares grew 14.3% in a year , partly from a public offering of roughly 23 million shares at $12 apiece — dilution that existing shareholders absorbed to fund trials.

  • A Big Short Position Adds Fuel and Risk. Some 17.5% of outstanding shares are sold short , meaning nearly one in five shares is a bet against the stock. That creates potential for a short squeeze — where bearish traders are forced to buy shares to cover losses, amplifying upward moves like today's. With the stock up more than 430% in the past year , shorts have been punished, but any clinical setback could quickly reverse the momentum. The Phase 3 readout remains the make-or-break event investors are truly pricing.